Sensitization of renal transplant candidates by cryopreserved cadaveric venous or arterial allografts1

Lopez‐Cepero, Mayra; Sanders, Charles E.; Buggs, Jacentha; Bowers, Victor

doi:10.1097/00007890-200203150-00029

Cited by 20 publications

(22 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strong anti-MHC class I and class II antibody production was observed in the sera of non-immunosuppressed end-stage renal disease patients with an allovenous haemodialysis access [20]. Moreover, the donor-specific anti-MHC class I and class II antibody response was also seen after valved allograft implantation in children with congenital heart disease [21].…”

Section: Discussionmentioning

confidence: 95%

Antibody-Mediated Rejection of Arterialised Venous Allografts Is Inhibited by Immunosuppression in Rats

Splith¹,

Fellmer

Matia

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Objectives and DesignWe determined in a rat model (1) the presence and dynamics of alloantibodies recognizing MHC complexes on quiescent Brown-Norway (BN) splenic cells in the sera of Lewis (LEW) recipients of Brown-Norway iliolumbar vein grafts under tacrolimus immunosuppression; and (2) the presence of immunoglobulins in the wall of acute rejected vein allografts.Materials and MethodsFlow cytometry was used for the analysis of day 0, 14 and 30 sera obtained from Lewis recipients of isogeneic iliolumbar vein grafts (group A) or Brown-Norway grafts (group B, C) for the presence of donor specific anti-MHC class I and II antibodies. Tacrolimus 0.2 mg/kg daily was administered from day 1 to day 30 (group C). Histology was performed on day 30.ResultsSera obtained preoperatively and on day 30 were compared in all groups. The statistically significant decrease of anti MHC class I and II antibody binding was observed only in allogenic non-immunosuppressed group B (splenocytes: MHC class I - day 0 (93%±7% ) vs day 30 (66%±7%), p = 0.02, MHC class II - day 0 (105%±3% ) vs day 30 (83%±5%), p = 0.003; B-cells: MHC class I - day 0 (83%±5%) vs day 30 (55%±6%), p = 0.003, MHC class II - day 0 (101%±1%) vs day 30 (79%±6%), p = 0.006; T-cells: MHC class I - day 0 (71%±7%) vs day 30 (49%±5%), p = 0.04). No free clusters of immunoglobulin G deposition were detected in any experimental group.ConclusionArterialized venous allografts induce strong donor-specific anti-MHC class I and anti-MHC class II antibody production with subsequent immune-mediated destruction of these allografts with no evidence of immunoglobulin G deposition. Low-dose tacrolimus suppress the donor-specific antibody production.

show abstract

Section: Discussionmentioning

confidence: 95%

Antibody-Mediated Rejection of Arterialised Venous Allografts Is Inhibited by Immunosuppression in Rats

Splith¹,

Fellmer

Matia

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…This difference in outcome could also be explained by immunologic mechanisms. Artificial dialysis membranes and vascular access might potentially contribute to increased sensitization in transplant candidates (45). While this study probably does not provide enough evidence to recommend exclusive use of PD for RRT in SLE patients eligible for transplant, more research in this area is probably warranted and might provide stronger evidence for the optimal RRT modality selection.…”

Section: Discussionmentioning

confidence: 99%

Factors affecting kidney‐transplant outcome in recipients with lupus nephritis

Tang¹,

Chelamcharla

Baird

et al. 2007

Clinical Transplantation

View full text Add to dashboard Cite

In renal transplant recipients with lupus nephritis, multiple pregnancies, multiple blood transfusions, greater comorbidity index, higher body weight, age and African American race of the donor or recipient, prior history of transplantation, greater PRA levels, lower level of HLA matching, deceased donors, and HD in pretransplant period have an association with increased risk of graft failure. Similarly, higher recipient and donor age, prior transplantations, and higher rate of pretransplant transfusions are associated with greater risk of recipient mortality. Using neither cyclosporine nor tacrolimus or using both (compared with tacrolimus) and neither MPA nor azathioprine (compared with azathioprine) was associated with increased risk of graft failure and recipient death. Using MPA is associated with greater risk of recipient death compared with azathioprine. Testing these results in a prospective study might provide important information for clinical practice.

show abstract

“…the indirect specification of anti-HLA alloantibodies using a panel of HLAtyped testing cells. This was illustrated in a recent study analyzing allosensitization by cryopreserved cadaveric venous or arterial allografts for haemodialysis access using purified HLA antigen-coated beads (11).…”

Section: Acknowledgmentsmentioning

confidence: 99%

Donor‐specific sensitization by cadaveric venous allografts used for arterial reconstruction in peripheral arterial occlusive vascular disease

et al. 2004

View full text Add to dashboard Cite

The use of allogeneic venous grafts from postmortal organ donors allows for the reconstruction of critically affected arteries in patients with peripheral occlusive vascular disease. We were interested to determine the prevalence and specificity of anti-HLA antibodies in patients after allogeneic vein transplantation. Anti-HLA class I and II alloantibodies were analyzed by flowcytometric analysis using color-coded microbeads coated with HLA antigens including recombinant single antigens. Nine out of 10 patients involving 12 venous allografts were positive for anti-HLA alloantibodies. All antibody-positive patients carried both anti-HLA class I and II alloantibodies. Anti-donor HLA specificity of the anti-HLA alloantibodies was seen in seven out of nine patients for anti-class I antibodies and in eight out of nine patients for anti-HLA class II antibodies. A high rate of donor-specific allosensitization was seen after allogeneic venous transplantation. In conclusion, allosensitization not only includes a humoral response against the constitutively expressed class I antigens but also extends to class II antigens.

show abstract

Sensitization of renal transplant candidates by cryopreserved cadaveric venous or arterial allografts1

Abstract: Recipients of cadaveric venous or arterial allografts elicit an HLA antibody response attesting to the antigenicity of cryopreserved cadaveric allografts.

Cited by 20 publications

References 5 publications

Antibody-Mediated Rejection of Arterialised Venous Allografts Is Inhibited by Immunosuppression in Rats

Antibody-Mediated Rejection of Arterialised Venous Allografts Is Inhibited by Immunosuppression in Rats

Factors affecting kidney‐transplant outcome in recipients with lupus nephritis

Donor‐specific sensitization by cadaveric venous allografts used for arterial reconstruction in peripheral arterial occlusive vascular disease

Contact Info

Product

Resources

About